A study has analyzed how plasma DPP-4 activity and levels of soluble DPP-4 correlate with inflammatory markers (C-reactive protein [CRP], IL-6, TNF-, and monocyte chemoattractant protein-1 [MCP-1]) in a subset of patients with T2DM treated with sitagliptin for 12 months as part of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS, 26)
Recalls & Warnings October 08, 2024 AK Forte Joint Pain Supplement Recalled On October 8, 2024, C&A Naturistics voluntarily recalled all lots of AK Forte, 400 mg tablets because FDA laboratory analysis found products to contain undeclared diclofenac, dexamethasone, and methocarbamol
Endocrinology 1995;136:358596.ArticlePubMed 5
In February 2025, the FDA announced that the shortage of semaglutide injectable products (Ozempic, Wegovy) was resolved